- Home
- MEIP vs IBIO Comparison
MEIP vs IBIO Comparison
Compare MEIP & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- IBIO
- Stock Information
- Founded
- MEIP 2000
- IBIO 2008
- Country
- MEIP United States
- IBIO United States
- Employees
- MEIP N/A
- IBIO N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MEIP Health Care
- IBIO Health Care
- Exchange
- MEIP Nasdaq
- IBIO Nasdaq
- Market Cap
- MEIP 13.3M
- IBIO 15.9M
- IPO Year
- MEIP 2003
- IBIO N/A
- Fundamental
- Price
- MEIP $2.53
- IBIO $0.78
- Analyst Decision
- MEIP Hold
- IBIO Strong Buy
- Analyst Count
- MEIP 1
- IBIO 3
- Target Price
- MEIP N/A
- IBIO $4.87
- AVG Volume (30 Days)
- MEIP 21.5K
- IBIO 5.4M
- Earning Date
- MEIP 05-13-2025
- IBIO 05-02-2025
- Dividend Yield
- MEIP N/A
- IBIO N/A
- EPS Growth
- MEIP N/A
- IBIO N/A
- EPS
- MEIP N/A
- IBIO N/A
- Revenue
- MEIP N/A
- IBIO $375,000.00
- Revenue This Year
- MEIP N/A
- IBIO $36.00
- Revenue Next Year
- MEIP N/A
- IBIO N/A
- P/E Ratio
- MEIP N/A
- IBIO N/A
- Revenue Growth
- MEIP 33.76
- IBIO 650.00
- 52 Week Low
- MEIP $1.46
- IBIO $0.64
- 52 Week High
- MEIP $4.10
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- IBIO 37.70
- Support Level
- MEIP $2.21
- IBIO $0.68
- Resistance Level
- MEIP $2.95
- IBIO $1.04
- Average True Range (ATR)
- MEIP 0.15
- IBIO 0.12
- MACD
- MEIP 0.05
- IBIO -0.00
- Stochastic Oscillator
- MEIP 81.48
- IBIO 7.89
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.